Valproic acid is widely used as a mood stabilizer. We report a case of an adult with bipolar disorder taking therapeutic doses of valproic acid, who presented to the emergency department with coma related to hyperammonemia as a complication of valproic acid treatment. Valproic acid was discontinued which resulted in rapid clinical recovery. Valproic acid induced coma was likely related to a urea cycle enzymopathy. Clinicians should consider hyperammonemia in all patients who present with coma and other mental status changes while on valproic acid. In such patients, ammonia level should be obtained in addition to liver function tests.
SadockBJSadockVA. Comprehensive Textbook of Psychiatry, Seventh Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
2.
CoulterDLAllenR. Hyperammonemia with valproic acid therapy. The Journal of Pediatrics1981;99:317–319.
3.
CoudeFXRabierDCathelineauL. Letter to the editor: A mechanism for valproate-induced hyperammonemia. Pediatric Research1981;15:974–975.
4.
RawatSBorkowskiWSwickH. Valproic acid and secondary hyperammonemia. Neurology1981;31:1173–1174.
5.
OhtaniYEndoFMatsudaI. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. The Journal of Pediatrics1982;101:782–785.
6.
ZaretBSBecknerRRMariniAMWagleWPassarelliC. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology1982;32(2):206–208.
7.
DuarteJMaciasSCoriaFFernandezEClaveriaLE. Valproate-induced coma: Case report and literature review. The Annals of Pharmacotherapy1993;27(5):582–583.
8.
KondoTIshidaMKanekoSHiranoTOtaniKFukushimaYMuranakaHKoideNYokoyamaMNakataS. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?Epilepsy1992;33(3):550–554.
9.
HoneycuttDCallahanKRutledgeL. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology1992;42:666–668.
10.
LeaoM. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology1995;45:593–594.
11.
SettleECJr. Valproate acid-associated encephalopathy with coma. American Journal of Psychiatry1995;152(8):1236–1237.
12.
RabyWN. Carnitine for valproic acid-induced hyperammonemia. American Journal of Psychiatry1997;154(8):1168–1169.
13.
OechsnerMSteenCSturenburgHJKohlschutterA. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognized ornithine transcarbamylase deficiency. Journal of Neurology Neurosurgery Psychiatry1998;64:680–682.
14.
EzeEWorkmanMDonleyB. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatry Services1998;49:1358–1359.
15.
PanikkarPGilmanM. Valproate-induced hyperammonemia in the psychiatric setting: 2 Cases. Journal of Clinical Psychiatry1999;60(8):557–559.
16.
RaskindJEl-ChaarG. The role of carnitine supplementation during valproic acid therapy. The Annals of Pharmacotherapy2000;34:630–638.
